

Compound A attenuates vincristine-induced pain
Day 5
Day 9
Day 12
log PWT (g)
15
10
5
3
45%
**
42%
*
39%
Vehicle
Vehicle
25
50
Vincristine

FIG. 1



Compound B attenuates vincristine-induced pain
Day 3
Day 6
Day 10
log PWT (g)
15
10
5
3
2
45%
***
28%
*
41%
***
47%
***
58%
***
Vehicle
Vehicle
25
50
Vincristine

FIG. 2



Oxaliplatin mechanical allodynia
CT (N=5)
Oxali (N=6)
CT + 50 mg/kg Compound C (N=5)
Oxali + 50 mg/kg Compound C (N=6)
Mechanical Allodynia
Paw Withdrawal Threshold (g)
0
1
2
3
4
5
#
*
BL
WK 3
WK 6
WK 8
Testing Session

FIG.3



CT (N=3)
Oxali (N=4)
CT + 50 mg/kg Compound C (N=3)
Oxali + 50 mg/kg Compound C (N=4)
Compound C attenuates oxaliplatin cold allodynia
Paw Lifts (#) in 5 min
60
45
30
15
0
#
BL
WK 3
WK 6
WK 8
Testing Session

FIG.4



Cisplatin mechanical allodynia
CT (N=7)
Cis (N=8)
CT + 50 mg/kg Compound C (N=7)
Cis + 50 mg/kg Compound C (N=8)
Cis + 25 mg/kg Compound C (N=8)
Paw Withdrawal Threshold (g)
0
1
2
3
4
5
BL
WK 3
WK 6
WK 8
Testing Session
*
***
***
***
*
*
**
***

FIG.5



CT (N=5)
Cis (N=5)
CT + 50 mg/kg Compound C (N=5)
Cis + 50 mg/kg Compound C (N=5)
Cis + 25 mg/kg Compound C (N=2)
Compound C attenuates cisplatin heat hyperalgesia
Paw Withdrawal Latency (s)
10
8
6
4
2
0
#
*
#
BL
WK 3
WK 6
WK 8
Testing Session

FIG.6



PARP Inhibitor, Compound A attenuates vincristine–induced pain
Day 5
Day 9
Day 12
Log PWT (g)
15
10
5
3
2
***
S
V
25
50
M
Vincristine

FIG. 7

Compound A prevented vincristine-mediated increase in PAR levels in skin




FIG.8

PARP Inhibitor, Compound C, prevented cisplatin-induced decrease in digital nerve SNAP recording




FIG.9